Differentiated effects of the multimodal antidepressant vortioxetine on sleep architecture: Part 1, a pharmacokinetic/pharmacodynamic comparison with paroxetine in healthy men
Authors:
Open Access
- 7 August 2015
- journal article
- research article
- Published by SAGE Publications in Journal of Psychopharmacology
- Vol. 29 (10) , 1085-1091
Abstract
We compared the effect of vortioxetine, paroxetine and placebo after three days of dosing on sleep architecture. This was a randomised, double-blind, four-way crossover, placebo-controlled, multiple-dose study in 24 healthy young men. Subjects received 20mg vortioxetine, 40mg vortioxetine, 20mg paroxetine or placebo for three consecutive days in four different periods with at least three weeks between them. Polysomnography and blood sampling for pharmacokinetic analysis were performed on the pre-dose night and nights 1 and 3 of dosing in each period. Plasma concentrations of vortioxetine and paroxetine during the polysomnography measurement were used to estimate SERT occupancies using published relationships in healthy subjects. All three active treatments significantly increased REM onset latency and decreased time spent in REM sleep. In the pharmacokinetic/pharmacodynamics analysis significant relationships were found between REM onset latency and time spent in REM sleep and vortioxetine/paroxetine exposure. The relation between REM suppression parameters and SERT occupancy was significantly different between vortioxetine and paroxetine, despite the same SERT occupancy. This indicates that vortioxetine has a different clinical pharmacological profile from paroxetine, which may explain the differences in adverse effect profile of the two drugs, for instance the lower incidence of nausea, weight gain and sexual dysfunction with vortioxetine.Keywords
This publication has 23 references indexed in Scilit:
- Discovery of 1-[2-(2,4-Dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): A Novel Multimodal Compound for the Treatment of Major Depressive DisorderJournal of Medicinal Chemistry, 2011
- Activation of the serotonin 5-HT3 receptor in the dorsal raphe nucleus suppresses REM sleep in the ratProgress in Neuro-Psychopharmacology and Biological Psychiatry, 2008
- Population pharmacokinetic model of fluvoxamine in rats: Utility for application in animal behavioral studiesEuropean Journal of Pharmaceutical Sciences, 2007
- The use of sleep measures to compare a new 5HT1A agonist with buspirone in humansJournal of Psychopharmacology, 2005
- Antidepressants and SleepDrugs, 2005
- 5-HT1A/1B Receptor-Mediated Effects of the Selective Serotonin Reuptake Inhibitor, Citalopram, on Sleep: Studies in 5-HT1A and 5-HT1B Knockout MiceNeuropsychopharmacology, 2002
- Fluoxetine and Sleep EEG Effects of a Single Dose, Subchronic Treatment, and Discontinuation in Healthy SubjectsNeuropsychopharmacology, 2002
- Effects of the selective activation of 5-HT3 receptors on sleep: a polysomnographic study in healthy volunteersEuropean Neuropsychopharmacology, 2001
- Proposed supplements and amendments to ‘A Manual of Standardized Terminology, Techniques and Scoring System for Sleep Stages of Human Subjects’, the Rechtschaffen & Kales (1968) standardPsychiatry and Clinical Neurosciences, 2001
- The influence of ipsapirone, a 5-HT1A agonist, on sleep patterns of healthy subjectsPsychopharmacology, 1995